Peanut allergic study participants between the ages of 12 and 55 years will be randomly assigned to one of two groups. Initially, one group will receive tezepelumab and the other will receive placebo. After 8 weeks, peanut OIT will be added to each group for a period of 56 weeks. Then, participants will stop taking tezepelumab/placebo and OIT for 12 weeks. Allery to peanut will be assessed three times by food challenge during the study: -At screening to assess peanut allergy -The end of the 56-week combination therapy period -Following the 12-week experimental drug withdrawal Throughout the study, blood, urine, and saliva samples will be collected, and skin prick testing will be conducted.